Moderna
MRNA
979 hedge funds and large institutions have $34.9B invested in Moderna in 2022 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 346 increasing their positions, 355 reducing their positions, and 113 closing their positions.
4% more funds holding in top 10
Funds holding in top 10: 23 → 24 (+1)
0.22% less ownership
Funds ownership: 61.69% → 61.47% (-0.22%)
2% less call options, than puts
Call options by funds: $2.04B | Put options by funds: $2.07B
3% less repeat investments, than reductions
Existing positions increased: 346 | Existing positions reduced: 355
3% less funds holding
Funds holding: 1,006 → 979 (-27)
16% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 113
20% less capital inflows, than outflows
Capital inflows: $2.19B | Capital outflows: $2.73B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$581M |
| 2 |
Goldman Sachs
New York
|
+$165M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$139M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Flagship Pioneering
Cambridge,
Massachusetts
|
-$671M |
| 2 |
BlackRock
New York
|
-$351M |
| 3 |
Renaissance Technologies
New York
|
-$234M |
| 4 |
D.E. Shaw & Co
New York
|
-$175M |
| 5 |
Coatue Management
New York
|
-$175M |
MRNA Hedge Fund Activity: Q2 2022 in Review
979 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q2 2022, worth a combined $34.9B — down 18% from $42.8B a quarter earlier.
Sellers outnumbered buyers: 113 funds closed out of MRNA and 95 opened new positions — a net loss of 18 holders — while 355 trimmed existing stakes and 346 added.
The largest buyer was Wellington Management Group, adding an estimated $581M. The largest seller was Flagship Pioneering, cutting an estimated $671M.
- 979 institutional investors held Moderna (MRNA) as of Q2 2022, down from 1,006 in Q1 2022.
- Funds reported $34.9B of Moderna stock for Q2 2022, down 18% quarter-over-quarter.
- 95 funds opened new Moderna positions in Q2 2022 and 113 closed out, a net change of -18 holders.
- The largest Moderna buyer in Q2 2022 was Wellington Management Group, an estimated $581M added.
- The largest Moderna seller in Q2 2022 was Flagship Pioneering, an estimated $671M sold.
Based on aggregated 13F filings for Q2 2022.